Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionNorth Star Asset Management Inc
Latest Disclosed Ownership1,103 shares
Latest Disclosed Value $ 364,950
North Star Asset Management Inc reports 0.18% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 6, 2026 - North Star Asset Management Inc filed a 13F-HR form disclosing ownership of 1,103 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $315,127 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 1,105 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -0.18% during the quarter. The current value of the position is $287,332 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,103 -2 -0.18 365 -17.08 0.0095
2026-02-09 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,105 -200 -15.33 439 -26.22 0.0177
2025-11-10 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,305 0 0.00 595 40.00 0.0241
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,305 0 0.00 426 20.74 0.0180
2025-05-08 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,305 -5 -0.38 352 14.29 0.0161
2025-02-19 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,310 0 0.00 308 -14.44 0.0136
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,310 0 0.00 360 13.21 0.0162
2024-08-05 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,310 -200 -13.25 318 41.33 0.0151
2024-05-08 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,510 -5 -0.33 226 -22.15 0.0107
2024-02-01 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,515 0 0.00 290 7.84 0.0148
2023-10-26 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,515 0 0.00 268 -6.62 0.0154
2023-08-09 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,515 -25 -1.62 288 -6.82 0.0159
2023-05-10 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,540 0 0.00 308 -15.62 0.0181
2023-03-06 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,540 0 0.00 366 18.51 0.0227
2022-11-08 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,540 -500 -24.51 308 3.36 0.0211
2022-07-28 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,040 20 0.99 298 -9.70 0.0196
2022-04-29 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,020 0 0.00 330 -3.79 0.0173
2022-02-07 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,020 0 0.00 343 -9.97 0.0173
2021-10-20 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,020 20 1.00 381 12.39 0.0209
2021-07-30 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 339 20.21 0.0188
2021-04-29 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 282 8.46 0.0169
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 260 -10.65 0.0164
2020-11-02 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 0 0.00 291 -1.69 0.0215
2020-07-28 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,000 -1,000 -33.33 296 -9.48 0.0235
2020-04-24 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,000 0 0.00 327 -5.49 0.0315
2020-02-06 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,000 0 0.00 346 43.57 0.0249
2019-10-25 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,000 -1,000 -25.00 241 -16.90 0.0189
2019-08-12 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,000 0 0.00 290 -22.46 0.0226
2019-04-26 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,000 4,000 374 0.0303
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.